1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid | 32275-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
• 英文别名: 4,5,6,7-tetrahydro-1-phenyl-1H-indazole-3-carboxylic acid；1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid；1-Phenyl-4,5,6,7-tetrahydro-1H-indazol-3-carbonsaeure；1-Phenyl-4,5,6,7-tetrahydro-1H-indazol-carbonsaeure-(3)；1-phenyl-4,5,6,7-tetrahydroindazole-3-carboxylic acid
• CAS: 32275-63-1
• 化学式: C₁₄H₁₄N₂O₂
• mdl: MFCD08277203
• 分子量: 242.277
• InChiKey: RTQVNHMXVLFXIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid 生成 1-苯基-4,5,6,7-四氢-1H-吲唑
  参考文献：
  名称：

  v. Auwers, Justus Liebigs Annalen der Chemie, 1927, vol. 453, p. 228

  摘要：

  DOI：
• 作为产物：
  描述：

  D-galactose phenylhydrazone 在 sodium hydroxide 、 sodium periodate 、 silver nitrate 作用下， 以 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 376.0h， 生成 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
  参考文献：
  名称：

  d-半乳糖苯基hydr与硝基烯烃的反应：五羟基戊基吡唑的合成

  摘要：

  摘要d-半乳糖苯基hydr与1-和2-取代的和1,2-二取代的硝基烯烃反应，失去硝基，得到中等产率的3-（d-半乳糖-戊糖醇-1-基）-1 -苯基吡唑在4、5和4，5位上被不同取代，并提出了机理。这些产物的乙酰化得到五乙酸酯，高碘酸酯氧化得到相应的1-苯基吡唑-3-甲醛衍生物，其中一些被氧化成羧酸。Uv，ir和nmr数据证实了所提出的结构。

  DOI：

  10.1016/0008-6215(88)80058-2

文献信息

• 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：RUF Sven

  公开号：US20130053416A1

  公开（公告）日：2013-02-28

  3-Heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula I, wherein Ht, G, R 10 , R 30 , R 40 , R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  3-杂环酰氨基丙酸衍生物及其作为药物的用途。本发明涉及具有以下式I的化合物，其中Ht，G，R10，R30，R40，R50和R60具有权利要求中所示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备具有式I的化合物的方法，它们的用途以及包含它们的药物组合物。
• Wnt signaling pathway inhibitors for treatments of disease
  申请人：UNIVERSITY OF MARYLAND, BALTIMORE

  公开号：US10882841B2

  公开（公告）日：2021-01-05

  Compounds and compositions are provided as inhibitors of the Wnt/β-catenin pathway for the treatment of diseases that implicate the same.

  提供了作为 Wnt/β-catenin 通路抑制剂的化合物和组合物，用于治疗涉及 Wnt/β-catenin 通路的疾病。
• Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation
  作者：Wei Yang、Yingjun Li、Yong Ai、Obinna N. Obianom、Dong Guo、Hong Yang、Srilatha Sakamuru、Menghang Xia、Yan Shu、Fengtian Xue

  DOI：10.1021/acs.jmedchem.9b01252

  日期：2019.12.26

  Dysregulation of the Wnt/beta-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of beta-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.
• GOMEZ, GUILLEN MANUEL;JIMENEZ, CONDE JUAN L., CARBOHYDR. RES., 180,(1988) N 1, C. 1-17
  作者：GOMEZ, GUILLEN MANUEL、JIMENEZ, CONDE JUAN L.

  DOI：——

  日期：——
• WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE
  申请人：University of Maryland, Baltimore

  公开号：EP3423452A1

  公开（公告）日：2019-01-09